Abstract

BackgroundWe evaluated the therapeutic effect and fate of high doses of human umbilical cord Wharton jelly cells (hUCWJCs) after IP administration to streptozotocin (STZ)-induced diabetic mice.MethodsType 1 diabetes (T1D) was induced in Kunming mice via IP injection of STZ. hUCWJCs were labeled with 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI). Diabetic animals with sustained hyperglycemia for at least 2 weeks were administered 1 × 107 Dil-hUCWJCs via intraperitoneal injection. Insulin, glucagon and PDX-1 were detected by immunofluorescence with confocal microscopy. Serum mouse and human C-peptide was assayed in blood collected via intracardiac puncture. Specific β-cell differentiation markers and human DNA were assessed using qPCR performed with 200 ng of target DNA.ResultshUCWJCs migrated to the STZ-damaged organs and contributed to lower blood glucose levels in 30% of the treated mice. Confocal microscopy revealed the presence of resident insulin-positive cells in the liver and kidneys. hUCWJC-treated mice with restored hyperglycemia also showed increased serum mouse C-peptide levels. The qPCR results, particularly in the liver, revealed that after transplantation hUCWJCs upregulated genes of endocrine precursors but failed to express endocrine stage markers. Mice with restored hyperglycemia had reduced urinary volume and lacked glomerular hypertrophy, exhibiting a morphology resembling that of normal glomeruli. Moreover, we also verified that one of the possible mechanisms by which hUCWJCs exert immunosuppressive effects is through down-regulation of the cell surface receptor HLA-1.ConclusionsWe confirmed the potential of IP administration of hUCWJCs and the capability of these cells to migrate to damaged tissues and promote insulin secretion from non-pancreatic local cells and to improve renal damage. These findings confer unique therapeutic properties to hUCWJCs, suggesting a promising future in the treatment of diabetes mellitus.

Highlights

  • We evaluated the therapeutic effect and fate of high doses of human umbilical cord Wharton jelly cells after IP administration to streptozotocin (STZ)-induced diabetic mice

  • Due to the mentioned limitations, the use of embryonic stem cells (ESCs), cord blood–derived SCs, adult SCs, bone marrow, genetically engineered cells and mesenchymal stem cells (MSCs) among others are under exhaustive testing with the aim of reversing hyperglycemia [1, 3, 19, 22, 46, 56,57,58]

  • Characterization of human umbilical cord Wharton jelly cells (hUCWJCs) hUCWJCs remained as a monolayer on the culture plate during the sub-culturing process and were efficiently maintained in vitro with robust proliferation

Read more

Summary

Introduction

We evaluated the therapeutic effect and fate of high doses of human umbilical cord Wharton jelly cells (hUCWJCs) after IP administration to streptozotocin (STZ)-induced diabetic mice. The reversal of T1D involves whole pancreas or islet cell transplantation in association with nonspecific immunosuppressive therapy [38]. Due to the mentioned limitations, the use of embryonic stem cells (ESCs), cord blood–derived SCs, adult SCs, bone marrow, genetically engineered cells and mesenchymal stem cells (MSCs) among others are under exhaustive testing with the aim of reversing hyperglycemia [1, 3, 19, 22, 46, 56,57,58]. Among the different types of MSCs, Human Umbilical Cord Wharton Jelly Cells (hUCWJCs) appear to offer the best clinical advantage due to their unique beneficial characteristics [5].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call